Pharmaceuticals Market Research Reports & Industry Analysis

Publications found: 36,694

Sort by:

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H1 2018

US$ 3,500.00

... molecule type. It also reviews key players involved in Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) targeted therapeutics development with respective active and ...

April 2018 34 pages

Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Pipeline Review, H1 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) development ...

April 2018 37 pages

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H1 2018

US$ 3,500.00

... Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

April 2018 55 pages

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Pipeline Review, H1 2018

US$ 3,500.00

... players involved in Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics development ...

April 2018 69 pages

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H1 2018

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) development landscape Develop and ...

April 2018 61 pages

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2018

US$ 3,500.00

... players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) development ...

April 2018 98 pages

Global Human Growth Hormone Deficiency (GHD) Drugs Market Assessment: Current Market, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2023

US$ 1,800.00

... Analysis Global human Growth Hormone Deficiency (GHD) Pipeline Drugs Market – Sizing and Growth Actual Period: 2013-2017 Forecast Period: 2018-2023 Regional Analysis - Human Growth Hormone Deficiency (GHD ...

April 2018 130 pages

Asia-Pacific Chlorhexidine Gluconate (CHG) Solution Market by Manufacturers, Regions, Type and Application, Forecast to 2023

US$ 4,480.00

... Others There are 19 Chapters to deeply display the Asia-Pacific Chlorhexidine Gluconate (CHG) Solution market. Chapter 1, to describe Chlorhexidine Gluconate (CHG) Solution Introduction, product type and application, market overview, market ...

April 2018 105 pages

Pediatric Vaccines Market: United States Industry Analysis, Trends, Opportunity, Market Size and Segment Forecasts, 2018 - 2025

US$ 850.00

... programs and increased government funding for the vaccines development. “Pediatric Vaccines Market: United States Industry Analysis, Trends, Opportunity, Market Size and Segment Forecasts, 2018 - 2025 ...

April 2018 120 pages

Global Surgical Blades & Scalpels Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

US$ 3,480.00

... Other There are 15 Chapters to deeply display the global Surgical Blades & Scalpels market. Chapter 1, to describe Surgical Blades & Scalpels Introduction, product scope, market overview, market opportunities, market ...

April 2018 103 pages

North America and Europe All Vaccine Market by Manufacturers, Regions, Type and Application, Forecast to 2023

US$ 4,480.00

... SCOPE OF THE REPORT: This report focuses on the All Vaccine in North America and Europe market, especially in United States, United Kingdom, Canada, ... are 19 Chapters to deeply display the North America and Europe All Vaccine market. Chapter 1, to describe All Vaccine Introduction, product type and application, ...

April 2018 105 pages

North America and Europe Epinephrine Market by Manufacturers, Regions, Type and Application, Forecast to 2023

US$ 4,480.00

... SCOPE OF THE REPORT: This report focuses on the Epinephrine in North America and Europe market, especially in United States, United Kingdom, Canada, ... are 19 Chapters to deeply display the North America and Europe Epinephrine market. Chapter 1, to describe Epinephrine Introduction, product type and application, ...

April 2018 102 pages

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H1 2018

US$ 3,500.00

... Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

April 2018 80 pages

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Pipeline Review, H1 2018

US$ 3,500.00

... players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) development ...

April 2018 74 pages

Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Pipeline Review, H1 2018

US$ 3,500.00

... Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

April 2018 64 pages

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Pipeline Review, H1 2018

US$ 3,500.00

... 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics under development ...

April 2018 94 pages

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Pipeline Review, H1 2018

US$ 3,500.00

... , this report also reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics development with respective active and dormant ...

April 2018 71 pages

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H1 2018

US$ 3,500.00

... Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

April 2018 64 pages

Atypical Chemokine Receptor 3 (C-X-C Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3) - Pipeline Review, H1 2018

US$ 3,500.00

... this report also reviews key players involved in Atypical Chemokine Receptor 3 (C-X-C Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3) targeted therapeutics development with respective active and ...

April 2018 30 pages

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Pipeline Review, H1 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) development landscape ...

April 2018 36 pages

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - Pipeline Review, H1 2018

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) development landscape Develop and ...

April 2018 28 pages

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H1 2018

US$ 3,500.00

... C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

April 2018 44 pages

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H1 2018

US$ 3,500.00

... acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) development landscape Develop and design in-licensing and ...

April 2018 116 pages

Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Pipeline Review, H1 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) development ...

April 2018 60 pages

C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Pipeline Review, H1 2018

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) development landscape Develop and design ...

April 2018 51 pages

Human Papillomavirus Protein E6 (E6) - Pipeline Review, H1 2018

US$ 3,500.00

... Human Papillomavirus Protein E6 (E6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

April 2018 81 pages

Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Pipeline Review, H1 2018

US$ 3,500.00

... , this report also reviews key players involved in Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics development with respective active and ...

April 2018 78 pages

P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Pipeline Review, H1 2018

US$ 3,500.00

... also reviews key players involved in P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics development with respective ...

April 2018 44 pages

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Pipeline Review, H1 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) development ...

April 2018 155 pages

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Pipeline Review, H1 2018

US$ 3,500.00

... Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

April 2018 65 pages

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Pipeline Review, H1 2018

US$ 3,500.00

... Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

April 2018 49 pages

Asia-Pacific Botox Market by Manufacturers, Regions, Type and Application, Forecast to 2023

US$ 4,480.00

... the Asia-Pacific Botox market. Chapter 1, to describe Botox Introduction, product type and application, market overview, market analysis by countries, market opportunities, market risk, market driving force; Chapter 2, to analyze the manufacturers of Botox ...

April 2018 108 pages

Asia-Pacific Active Pharmaceutical Ingredients Market by Manufacturers, Regions, Type and Application, Forecast to 2023

US$ 4,480.00

... to deeply display the Asia-Pacific Active Pharmaceutical Ingredients market. Chapter 1, to describe Active Pharmaceutical Ingredients Introduction, product type and application, market overview, market analysis by countries, market opportunities, market risk, market driving force; Chapter ...

April 2018 103 pages

Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Pipeline Review, H1 2018

US$ 3,500.00

... ) and molecule type. It also reviews key players involved in Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics development with respective active and dormant ...

April 2018 59 pages

Glycoprotein 41 (gp41) - Pipeline Review, H1 2018

US$ 3,500.00

... and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Glycoprotein 41 (gp41) development landscape Develop and design in-licensing and ...

April 2018 67 pages

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H1 2018

US$ 3,500.00

... and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Catenin Beta 1 (Beta Catenin or CTNNB1) development landscape Develop and design in-licensing and ...

April 2018 57 pages

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H1 2018

US$ 3,500.00

... Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

April 2018 49 pages

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Pipeline Review, H1 2018

US$ 3,500.00

... effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) development landscape Develop and design in-licensing ...

April 2018 111 pages

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Pipeline Review, H1 2018

US$ 3,500.00

... D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

April 2018 68 pages

Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Pipeline Review, H1 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) development ...

April 2018 33 pages

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Pipeline Review, H1 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) development ...

April 2018 60 pages

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Pipeline Review, H1 2018

US$ 3,500.00

... Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

April 2018 42 pages

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H1 2018

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) development landscape Develop and design ...

April 2018 121 pages

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Review, H1 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) development landscape Develop ...

April 2018 99 pages

Global Human Coagulation Factor VIII Market by Manufacturers, Countries, Type and Application, Forecast to 2023

US$ 3,480.00

... Other There are 15 Chapters to deeply display the global Human Coagulation Factor VIII market. Chapter 1, to describe Human Coagulation Factor VIII Introduction, product scope, market overview, market opportunities, market ...

April 2018 108 pages

Global BCG Vaccine Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

US$ 3,480.00

... 2017; Chapter 4, to show the global market by regions, with sales, revenue and market share of BCG Vaccine, for each region, from 2013 to 2018; Chapter 5, 6, 7, 8 and 9, to analyze ...

April 2018 108 pages

2018 Italy Therapeutic Drug Monitoring (TDM) Market: Supplier Shares and Strategies, Country Test Volume and Sales Segment Forecasts

US$ 2,450.00

... report from VPGMarketResearch.com provides a comprehensive analysis of the Italian therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market ...

April 2018 247 pages

2018 Spain Therapeutic Drug Monitoring (TDM) Market: Supplier Shares and Strategies, Country Test Volume and Sales Segment Forecasts

US$ 2,450.00

... report from VPGMarketResearch.com provides a comprehensive analysis of the Spanish therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market ...

April 2018 249 pages

2018 UK Therapeutic Drug Monitoring (TDM) Market: Supplier Shares and Strategies, Country Test Volume and Sales Segment Forecasts

US$ 2,450.00

... -page report from VPGMarketResearch.com provides a comprehensive analysis of the UK therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market ...

April 2018 247 pages

2018 US Therapeutic Drug Monitoring (TDM) Market: Supplier Shares and Strategies, Country Test Volume and Sales Segment Forecasts

US$ 3,500.00

... -page report from VPGMarketResearch.com provides a comprehensive analysis of the US therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market ...

April 2018 249 pages

Filters

Clear all

Price

—

Date

—

Pages

—

Offers

Discount Offer from GMD Research

Special Offer from MP Advisors

Special Offer on Therapy Class R...